Clinical Trial of Neoadjuvant Targeted Treatment to NSCLC Patients
Status:
Not yet recruiting
Trial end date:
2026-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficiency and safety of Gefitinib Neoadjuvant
Therapy and Oral Navelbine Carboplatin Neoadjuvant Therapy for Resectable Stage Ⅱ-ⅢA NSCLC
patients with EGFR mutation.
Phase:
Phase 3
Details
Lead Sponsor:
Sun Yat-sen University
Collaborators:
Dongguan People's Hospital Maoming Affiliated Hospital of Southern Medical University Shenzhen People's Hospital Sixth Affiliated Hospital, Sun Yat-sen University